Profile

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,500+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Key Products

Viz.ai One is one unified AI-powered platform that serves many care teams and use cases to ensure patients receive the treatments they need, when and where they need it–before it’s too late.

Viz LVO for large vessel occlusion is the most reliable AI-powered triage software

that auto-detects suspected stroke within seconds of image acquisition. 90% of alerts are reviewed by the intended specialist within 5 minutes.

Viz HCM for hypertrophic cardiomyopathy is the first and only AI-powered software, cleared by the FDA, to detect signs of HCM and directs patients to the right specialist for faster diagnosis and treatment.

Customer Insights

“Recognizing the symptoms of serious vascular conditions, such as aortic dissections, is hugely important because any delay in treatment can have a direct impact on patient outcomes,” said Philip Batista (Cooper University Health Care, Camden, USA). “When Viz identifies an abnormal scan, it quickly notifies the appropriate specialists regardless of their location, facilitating seamless communication via mobile application. We have been using the Viz software for the last several months and have seen improvements in patient care across our institution.”

“Viz LVO will be nothing less than transformational when it comes to improving LVO detection in the United States, and I think that will happen quite quickly,” Devlin says. “By detecting the LVO and allowing us to communicate back and forth within the app, the software may lead to significant improvements in door to groin puncture times. In the past, outside hospitals would call us. Now, we automatically see the LVO at our stroke center and we call the hospital, facilitating patient transfer right away.”

“After implementing this software just a few months ago, we’ve already seen we are communicating with outside hospitals much more quickly,” Devlin says. “And we’re viewing images on our phone literally within minutes after a scan without waiting on other physicians to call us or waiting for an outside radiologist to read the images. This is facilitating change like no other application to come before it. It’s the most powerful, impactful technology I’ve seen in many years.”

Key Executives

Chris Mansi, MD, CEO, Co-Founded Viz.ai out of Stanford in 2016 with a mission of using artificial intelligence to increase access to life-saving treatments. Under his leadership, Viz.ai has achieved several AI industry milestones, including two de novo approvals by the FDA for AI computer aided triage in 2018 and cardiovascular machine learning-based notification software in 2023.

Jieun Choe, CMO, leads product management, user experience, and marketing at Viz.ai, collaborating to accelerate their go-to-market and patient impact.

Julie Skaff, COO, leads Regulatory, Implementation, Operations, and Support at Viz.ai and is passionate about advancing mission-driven healthcare IT companies that put patients first.

Mike Herring, CFO, is a seasoned financial executive with more than 30 years of experience. He most recently served as CFO at Color Health, a health technology company, where he led the financial infrastructure and operations teams to support the company’s growth and deliver critical medical care to millions during the COVID-19 pandemic.

Board Members

• Chris Mansi, MD, CEO and Co-Founder, Viz.ai


• Mamoon Hamid, Partner at Kleiner Perkins


• Mark Laret, President & CEO Emeritus at UCSF Health


• Rory O’Driscoll, Partner at Scale Venture Partners

Investors

Their last round was Series D in 2022. Tiger Global and Insight Partners led the round, joined by several of the company‘s early backers including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV, and Susa.

News and Press Releases

Oct 2023: Viz.ai Honored by Goldman Sachs for Entrepreneurship (Read)

Sep 2023: Viz.ai Announces Expansion into Outpatient Ambulatory Centers to Accelerate Clinical Trial Recruitment in Heart Failure (Read)

Sep 2023: New Clinical Data Supports Viz.ai Solution for Improved Pulmonary Embolism Detection and Care Coordination (Read)

Sep 2023: Viz.ai to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (Read)

Aug 2023: Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms (Read)

To know more about their latest news and press release, visit here.

Competitors

Tempus

Corporate Responsibility

Everything Viz.ai does is centered on improving patient care and outcomes. The company’s mission, “Increase access to life-saving treatments,” reflects its dedication to expanding access to critical medical interventions for patients everywhere. Viz.ai operates on core values: Patients First, Time is Brain, Quality Squared, Kindness Wins, and I am Accountable.

Half of Viz.ai’s executive team and 43% of its managers are women, highlighting the company’s commitment to equal opportunity hiring. Viz.ai actively works to increase diversity within its talent pool and workforce by partnering with organizations focused on diversity and maintaining an equitable and inclusive hiring process. The company prioritizes attracting and retaining top talent aligned with its mission of improving access to life-saving treatments.

Viz.ai supports its employees through various initiatives, including dedicated Slack channels for self-expression, the Viz Gives program, which aids hospitals serving underserved communities, and clear career path structures with growth opportunities. The company has received Comparably Awards in 2022, 2023, and 2024 for Best Company for Diversity, Career Growth, Work-Life Balance, Leadership, and Happiness, based on authentic employee feedback.